Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:33:06 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Q:CRNX - CRINETICS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRNX - Q0.752.08·54.123.153.10-0.04-0.1424.222,1656,36252.91  53.50  52.4055.78  25.7516:01:23Oct 1015 min RT 2¢

Recent Trades - Last 10 of 6362
Time ETExPriceChangeVolume
16:01:23Q53.10-0.04172
16:01:21Q53.10-0.04263
16:01:13Q53.10-0.04149
16:01:10Q53.10-0.04215
16:01:08Q53.10-0.04666
16:00:52Q53.10-0.04275
16:00:07Q53.10-0.044,422
16:00:07Q53.10-0.04512
16:00:07Q53.10-0.041,506
16:00:07Q53.10-0.0461

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-10 16:40U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-08 23:55U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2024-10-08 16:02U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2024-09-26 16:05U:CRNXNews ReleaseCrinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
2024-09-10 16:40U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-29 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2024-08-12 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-08 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-08-08 08:30U:CRNXNews ReleaseCrinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
2024-07-18 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
2024-07-10 19:30U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-18 16:30U:CRNXNews ReleaseEY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year(TM) 2024 Pacific Southwest Award Winner
2024-06-10 18:36U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-03 12:00U:CRNXNews ReleaseCrinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
2024-06-03 12:00U:CRNXNews ReleaseCrinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
2024-05-30 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
2024-05-22 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
2024-05-10 17:38U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-09 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-08 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024